Suppr超能文献

将随机对照试验作为制定治疗指南基础的局限性。

The limitations of using randomised controlled trials as a basis for developing treatment guidelines.

机构信息

Mood Assessment and Classification (MAC) Committee, Sydney, Australia.

Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.

出版信息

Evid Based Ment Health. 2018 Feb;21(1):4-6. doi: 10.1136/eb-2017-102701. Epub 2017 Jul 14.

Abstract

Randomised controlled trials (RCTs) are considered the 'gold standard' by which novel psychotropic medications and psychological interventions are evaluated and consequently adopted into widespread clinical practice. However, there are some limitations to using RCTs as the basis for developing treatment guidelines. While RCTs allow researchers to determine whether a given medication or intervention is effective in a specific patient sample, for practicing clinicians it is more important to know whether it will work for their particular patient in their particular setting. This information cannot be garnered from an RCT. These inherent limitations are exacerbated by biases in design, recruitment, sample populations and data analysis that are inevitable in real-world studies. While trial registration and CONSORT have been implemented to correct and improve these issues, it is worrying that many trials fail to achieve such standards and yet their findings are used to inform clinical decision making. This perspective piece questions the assumptions of RCTs and highlights the widespread distortion of findings that currently undermine the credibility of this powerful design. It is recommended that the clinical guidelines include advice as to what should be considered good and relevant evidence and that external bodies continue to monitor RCTs to ensure that the outcomes published indeed reflect reality.

摘要

随机对照试验(RCT)被认为是评估新型精神药物和心理干预措施的“金标准”,并因此被广泛应用于临床实践。然而,将 RCT 用作制定治疗指南的基础存在一些局限性。虽然 RCT 允许研究人员确定某种特定药物或干预措施在特定患者群体中的有效性,但对于临床医生来说,更重要的是要了解它是否会在他们特定的环境中对他们的特定患者有效。这些信息无法从 RCT 中获得。这些固有的局限性因设计、招募、样本人群和数据分析中的偏差而加剧,这些偏差在真实世界的研究中是不可避免的。虽然试验注册和 CONSORT 已被实施以纠正和改善这些问题,但令人担忧的是,许多试验未能达到这些标准,但它们的结果却被用于为临床决策提供信息。本文质疑了 RCT 的假设,并强调了目前广泛存在的扭曲发现的情况,这削弱了这种强大设计的可信度。建议临床指南中包含有关什么应该被视为良好和相关证据的建议,并且外部机构继续监测 RCT,以确保发表的结果确实反映了现实。

相似文献

2
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
PRECIS-2 for retrospective assessment of RCTs in systematic reviews.PRECIS-2 用于系统评价中 RCT 的回顾性评估。
J Clin Epidemiol. 2020 Oct;126:202-206. doi: 10.1016/j.jclinepi.2020.06.023. Epub 2020 Jun 19.
10
Randomised controlled trials: an introduction for nurse researchers.
Nurse Res. 2013 May;20(5):38-44. doi: 10.7748/nr2013.05.20.5.38.e312.

引用本文的文献

本文引用的文献

1
Lessons learned from Restoring Study 329: Transparent reporting, open databases and network meta-analyses as the way forward.
Aust N Z J Psychiatry. 2017 Apr;51(4):407-409. doi: 10.1177/0004867416676372. Epub 2016 Nov 19.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验